![Page 1: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/1.jpg)
Paul Sondel MD PhDUniversity of Wisconsin
Madison
Antibody Therapy: Biology, Immunocytokines, and Hematologic Malignancy
iSBTc PrimerBoston,
November 1, 2007
![Page 2: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/2.jpg)
DISCLOSURE STATEMENT
P. Sondel has disclosed the information listed below. Any real or apparent conflict of interest related to the content of the presentation
has been resolved.Organization AffiliationEMD-Pharmaceuticals Scientific AdvisorQuintesence Scientific AdvisorMedimmune Scientific Advisor
![Page 3: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/3.jpg)
Tumor Cell
Endothelium
Fibroblast
1.T-cellRecognition
T cell
MΦPMNNK cell
2. Innate ImmunityNKT cell
γδT Cell
Monoclonal Antibody
3. Passive Immunity
Treg cell
MUC16VEGFTGF-β
4. Tumor InducedImmune Suppression
T CellNK cell APC
5. Cellular Therapy
![Page 4: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/4.jpg)
Abbas and Lichtman:2003
Making Monoclonal Antibody (mAb)
![Page 5: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/5.jpg)
Underlying principle of mAbtherapy
SELECTIVE recognition of tumor cells, but not most normal cells by therapeutic mAb
![Page 6: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/6.jpg)
Clinically Relevant mAb target antigens
LEUKEMIA__ SOLID TUMOR
CD-20 B GD-2 NBL/Mel
CD-19 B Her2 Breast
CD-5 T EpCAM AdenoCA
![Page 7: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/7.jpg)
From Genes to Antibodies
![Page 8: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/8.jpg)
Antibody Engineering• First step - development of monoclonal antibodies
– Fusion of antibody-producing B cell with myeloma– Results in immortalized monospecific Ab-producing cell
line• Second step - ability to clone and re-express Abs
– Initially done with cloned, rearranged genes from hybridomas
– Parallel work with isolated Fab fragments in bacteria• Third step - re-engineering for desired properties
– Reducing immunogenicity of mouse antibodies– Tailoring size and half-life for specific need– Adding or removing functions
• Engineered diversity – phage display approach
From S. Gillies
![Page 9: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/9.jpg)
Chimeric Mouse-human antibodies
VH Human CLHuman CHVL
Mouse-derived
Human-derived
e.g. Erbitux
Fragment switched Fragment switched
From S. Gillies
![Page 10: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/10.jpg)
V Region “humanization”FR1 FR2 FR3 FR4
VHCDR1 CDR2 CDR3
FR1 FR2 FR3 FR4
VHCDR1 CDR2 CDR3
Human framework + mouse CDRs
Mouse V region
This approach has worked but often leads to mis-folding of CDRs requiring additional FR back-mutationsFrom S. Gillies
![Page 11: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/11.jpg)
Mechanisms of mAb mediated anti-tumor effects
![Page 12: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/12.jpg)
131I-3F8 binding to melanoma
Cheung et al. Biol Ther. Of Cancer, 1995
![Page 13: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/13.jpg)
![Page 14: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/14.jpg)
Bonner JA, Harari PM et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. NEJM, 354:634, 2006
(Anti-EGFR mAb)
p = 0.03
![Page 15: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/15.jpg)
![Page 16: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/16.jpg)
B cell
Mechanisms of anti-CD20 therapy: CDC
Rituximab
lipid raft
CD20
Complement fixationmembrane attack complex
From Dr. John Leonard - Cornell
![Page 17: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/17.jpg)
Abbas and Lichtman:2003
CD59 and S proteinInhibit MAC
![Page 18: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/18.jpg)
Complement mediated destruction is inhibited in vitro by CD59 (blocks MAC)
0%100%++++-NHL
90%100%++++++++NHL
Rituxan+ C’
Rituxan
ViabilityViabilityCD20CD59Tumor cell type
Treon et al . J. Immunother. 24:263, 2001
BUT, there is no correlation in vivo with CD59 and Rituxan response!
![Page 19: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/19.jpg)
B cell
Mechanisms of anti-CD20 therapy: ADCC
effectorcell
(NK, PMN or Mφ)
CD20
FcγRIIIA
Rituximab
From Dr. John Leonard - Cornell
![Page 20: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/20.jpg)
ITIM
ITA
M
ITA
M
ITA
M
ITA
M
Human Fcγ Receptor FamilyFcγRI FcγRIIA FcγRIIB FcγRIIIA FcγRIIIB
CD32 CD16
ITA
M
Dr. R. Clynes – Columbia U
![Page 21: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/21.jpg)
2 Major Types of Activating FcRfor IgG
• FcγRIIA (CD32)• Expressed on:
– Macrophages– PMNs
• Functions:– Phagocytosis– ADCC
• FcγRIIIA (CD16)• Expressed on:
– NK Cells• Functions:
– ADCC
![Page 22: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/22.jpg)
AA #158 of FcRIII V Higher Affinity for huIgGF Lower Affinity
PhenotypeV/VV/FF/F
In VitroADCC++++
+++
p < .05
Reponse RateIn Vivo to Rituxan
++++++
Efficacy of FcR influences in vivo Rituxan Effects
Cartron et al. Blood 99:754, 2002
![Page 23: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/23.jpg)
Copyright © American Society of Clinical Oncology
Weng, W.-K. et al. J Clin Oncol; 21:3940-3947 2003
Fig. 2
Kaplan-Meier estimates of progression-free survival by immunoglobulin G fragment Creceptor IIIa (Fc RIIIa) 158 valine (V)/phenylalanine (F) polymorphism.
Importance of FcγRIIIA on NK cells in Rituxan Therapy
![Page 24: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/24.jpg)
Copyright © American Society of Clinical Oncology
Weng, W.-K. et al. J Clin Oncol; 21:3940-3947 2003
Fig. 3
Kaplan-Meier estimates of progression-free survival (PFS) by immunoglobulin Gfragment C receptor IIa (Fc RIIa) 131 histidine (H)/arginine (R) polymorphism.
Importance of FcgRIIA on Mφs and PMNs cells in Rituxan Therapy
![Page 25: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/25.jpg)
Activate cells with FcγRIIA(PMNs and Mφs) with GM-CSF
• Treat with murine anti-GD2 mAb (3F8 or ch14.18) AND GM-CSF
• 3F8 is a murine IgG3 mAb:• Murine IgG3 mAb binds better to the
FcγRIIA-R131 than to the FcγRIIA-H131 allele
• Does the FcγRIIA allele status impact on outcome?
Cheung et al, JCO, 24:2885, 2006
![Page 26: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/26.jpg)
FCGR2A- R/R
FCGR2A- H/H or H/R
Pro
gres
sion
-free
sur
viva
l pro
babi
lity
Years from first 3F8-GMCSF treatment
MSKCC-IRB#9418, N=106, high-risk NB, no h/o prior relapse
P=0.023
Cheung et al, JCO,24:2885, 2006
The FcγRIIA allele status impacts outcome ONLY if GM-CSFis given (based on historical controls receiving 3F8 without GM-CSF.
![Page 27: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/27.jpg)
Activate NK cells to mediate ADCC
![Page 28: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/28.jpg)
CCG-0935/0935A-Pilot Phase-I study of ch14.18 + IL2 +
GM-CSF following ABMT for NBL
• Day 0 ABMT• Day 35 Ch14.18 + GM-CSF• Day 56 Ch14.18 + IL2• Day 77 Ch14.18 + GM-CSF• Day 98 Ch14.18 + IL2 • Day 119 Ch 14.18 + GM-CSF
– Ozkaynak et al JCO 18:4077, 2000– Gilman et al, Submitted 2007
![Page 29: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/29.jpg)
Schema: C.O.G. NBL Study ANBL0032 (2002)- A. Yu Chair
High Risk NBLHigh Risk NBL
InductionInduction
Ablation + Stem cell RescueAblation + Stem cell Rescue
RandomizeRandomize
ObserveObserve ch14.18 + GMch14.18 + GM--CSF + IL2CSF + IL2
CisCis--retinoic acidretinoic acid
![Page 30: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/30.jpg)
Tumor Cell
IL-2
IL-2 ReceptorT Cell
orNK Cell
GD2 Antigen
hu14.18-IL2
Anti-GD2+IL2Immunocytokine
(IC)
S. Gillies and R. ReisfeldClinical material made by NCI-BRB
![Page 31: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/31.jpg)
Efficacy of ch14.18-IL2 Immunocytokine against Murine Neuroblastoma Liver Metastases
# of
Liv
er M
ets
PBS Control0 1 2 3 4 5 6 7 8
0
50
100
150
200
250
ch14.18 + Il-20 1 2 3 4 5 6 7 8
0
50
100
150
200
250
ch14.18-Il-20 1 2 3 4 5 6 7 8
0
50
100
150
200
250123 + 69 34 + 21 0 + 0
Lode et al: J. Natl. Cancer Inst. 89:1586, 1997
![Page 32: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/32.jpg)
0
5
10
15
20
25
30
35
40
45
Pt 19 Pt 20 Pt 21
mediaPt serum C1D1prePt serum C1D1-4 hr
% C
ytot
oxic
ityAssays with Patient Effectors (C1D8) And Serum Pre and
Post hu14.18-IL2 Infusion (1144 Blood samples from 33pts)
King DM, Albertini MR, Schalch H, Hank JA, Surfus J, Mahvi D, Schiller JH, Warner T, Kim KM, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel PM. J.Clin.Onc. 22:4463,2004
ADCC of NBL targets
![Page 33: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/33.jpg)
0
250
500
750
1000
1250
1 2 3 4 8 15Day of Treatment
SIL-
2 R
ecep
tor α
C1 N = 28C2 N = 20C3 N = 15C4 N = 12
Soluble IL-2 receptor α level determined on days 1,2,3,4,8 and 15 of each course. Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM. Clinical Cancer Research, 12:1750, 2006.
COG study- 28 pts (1557 blood specimens evaluated).
![Page 34: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/34.jpg)
Conclusions from Phase I Trials hu14.18-IL2
• Dose, Schedule and MTD with acceptable toxicity found in pts. with NBL and MEL.
• MTD in children with NBL (heavily pretreated with chemo) is higher than MTD in adults, as expected. Similar PK.
• Hu14.18-IL2 induces immune activation in vivo (PBL, sIL2R, ADCC).
![Page 35: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/35.jpg)
Efficacy of ch14.18-IL2 Immunocytokine against Murine Neuroblastoma Liver Metastases
# of
Liv
er M
ets
PBS Control0 1 2 3 4 5 6 7 8
0
50
100
150
200
250
ch14.18 + Il-20 1 2 3 4 5 6 7 8
0
50
100
150
200
250
ch14.18-Il-20 1 2 3 4 5 6 7 8
0
50
100
150
200
250123 + 69 34 + 21 0 + 0
Lode et al: J. Natl. Cancer Inst. 89:1586, 1997
![Page 36: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/36.jpg)
0
50
100
150
200
250
P B S R x D ay 11 D ay 9 D ay 7 D ay 5
Num
ber
of L
iver
Met
asta
ses
hu14.18-IL2 (10ug/d) for 5 days starting on day 5, 7, 9, or 11 following 5 X 105 NXS2 cells injected on day 0, and harvested on day 28.
Hu14.18-IL2 Efficacy: Dependence on Minimal Tumor Status
Neal ZC, Yang JC, Rakhmilevich AL, Buhtoiarov I, Lum HE, Imboden M, Hank JA,Lode HN, Reisfeld RA, Gillies SD, Sondel PM. Enhanced activity of hu14.18-IL2 immunocytokine
against the murine NXS2 neuroblastoma when combined with IL2 therapy. Clinical Cancer Research, 10:4839-4847, 2004
![Page 37: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/37.jpg)
ANBL0322:ANBL0322:A Phase II Trial of the A Phase II Trial of the
HU14.18HU14.18--IL2 Fusion Protein in IL2 Fusion Protein in Children with Refractory Children with Refractory
NeuroblastomaNeuroblastomaPaul Sondel ChairPaul Sondel Chair
Suzy Shusterman Vice ChairSuzy Shusterman Vice Chair
![Page 38: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/38.jpg)
ANBL0322 Patient Accrual ANBL0322 Patient Accrual GoalsGoals
• Stratum 1 (n=20): residual/refractory NBL measurable by standard radiographic criteria
• *Stratum 2 (n=20): residual/refractory NBL not measurable by standard radiographic criteria, but evaluable by MIBG scanning or by bone marrow histology
• *Stratum 3 (n=20): residual/refractory neuroblastoma in clinical remission but with disease identified by BM ICC (>5 NBL cells per 1,000,000 cells)
*MRD Strata
![Page 39: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/39.jpg)
Clinically Approved MoAb for Cancer (2007)
Generic Brand Target Indication
Rituximab Rituxan CD20 B cell NHL____________________________________________________________________________Trastutumab Herceptin HER-2 HER-2 Breast CA____________________________________________________________________________Gemtuzumab Mylotarg CD33 AML
(mAb-toxin)____________________________________________________________________________Alemtuzumab Campath CD52 B-CLL, CTCL____________________________________________________________________________Ibritumomab Zevalin CD2 Refractory B NHLTosifumomab Bexxar (Radiolabeled mAb)____________________________________________________________________________Basiliximab/ Anti-TAC CD25 Anti-Graft Rejection/Daclizumab GVH____________________________________________________________________________Bevacizumab Avastin VEGF GI Malignancies____________________________________________________________________________Edrecolomab 17-1A EpCam GI Malignancies________________________________________________________________________Cetuximab Erbitux EGFR GI Malignancies____________________________________________________________________________
![Page 40: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/40.jpg)
• Include a mAb-containing regimen (possibly combined with other therapy) in the standard care for patients with high-risk cancers (i.e. likely to relapse)
• Goal – to prevent recurrence
Potential role for mAbs in standard therapy –
clinical goal
![Page 41: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/41.jpg)
• Some are already working! (ie: FDA approved components of standard therapy)
• Continued development and efficacy appear likely.
Antitumor applications of mAb
![Page 42: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/42.jpg)
1. The IMMUNOGENICITY of mAbs in patients
• Does the patient’s immune response (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?
Important issues not covered
![Page 43: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/43.jpg)
GD2Tumor Cell
hu14.18-PE
Patient Anti-id Aby
Idiotypic componentGD2
Patient Anti-id Antibody Inhibits Bindingof hu14.18 to Tumor cells
( Flow Cytometry Assay)
![Page 44: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/44.jpg)
(Adapted from S. Ferrone)
![Page 45: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/45.jpg)
2. The ability of tumors to ESCAPE from immunotherapy (ie: antigen loss or MHC modulation)
• Equivalent to selecting cancer cells with multi-drug resistance
Important issues not covered
![Page 46: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/46.jpg)
10 30
PBS
Hu14.18-IL2 5 mcg/d
NXS2 Free Miceon d 50
0/8
2/8
50
Suboptimal hu14.18-IL2 treatment causes transientantitumor effects in mice with palpable neuroblastomas
![Page 47: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/47.jpg)
0
20 0
40 0
60 0
80 0
100 0
120 0
140 0
C u ltu red N X S 2
h u 1 4 .1 8 -IL 2 -T reated R ecu rren t
S eries3
S eries4
H2Kk H2Dd
Mea
n Fl
uore
scen
ce In
tens
ity (M
FI)
Results: a > 9-fold increase in H2Kk expression and a > 10-fold increase in H2Dd expression
Neal et al. NXS2 NBL express increased MHC -I upon recurrence from NK dependent immunotherapy. Cancer Imm. and Imm. 53:41-52, 2004
![Page 48: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/48.jpg)
NK Cell
No killing
XNXS2Escapee
No activation
No MHC-I+ PeptideNKG2D MIC-A
TCR
T Cell
Killer InhibitoryReceptor
NXS2 Tumors modulate class I, down OR up,to escape T or NK mediated Immunotherapy
No killing
inhibition
MHC-I
IL2R
IC
FcR
Flt3-L
Neal et al. Canc. Imm. And Imm. 53:41, 2004
![Page 49: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/49.jpg)
Collaborators in UWCCC Immunocytokine Research-
2007• UWCCC– J Hank– M Albertini– J Gan– A Rakhmilevich– I Buhtoiarov– H Lum– H Schalch– D Mahvi– KM Kim– J Eickhoff– A Sternberg– S Dean– R Cassaday
• C.O.G and N.A.N.T.– Many Pediatric Oncologists
• Lexigen-EMD– S Gillies and colleagues
• EMD-Merck– B Clements– Karl Joseph Kallen– Many others
• Scripps– R Reisfeld
• NCI-BRB– Toby Hecht and colleagues
![Page 50: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/50.jpg)
UW-Pediatric Oncology Patient Reunion-Nov. 2003
PROOF THAT CANCER RESEARCH MAKES A DIFFERENCE!
![Page 51: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/51.jpg)
3. The potential for combining mAbtherapy with other immunotherapiesto prevent ESCAPE from immunotherapy
• Combine mAbs, or use mAbstogether with cytokines or vaccines
Important issues not covered
![Page 52: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/52.jpg)
4. The potential for combining mAbtherapy with other treatments (ChemoRx, RadioRx)
• Timing may be key. Should mAb be given during chemo cycle or after immune recovery?
Important issues not covered
![Page 53: Antibody Therapy: Biology, Immunocytokines, and ... · iSBTc Primer Boston, November 1, 2007. DISCLOSURE STATEMENT ... (HAMA, HACA, anti-id) HELP or HINDER the anti-tumor effect?](https://reader035.vdocuments.us/reader035/viewer/2022081521/5d1927f288c993495f8c3c61/html5/thumbnails/53.jpg)
Anti-tumor applications of mAb
Adapted from Cheung and Sondel 2005
4. Receptor blockade5. Signal transduction